Rigel Pharma (RIGL) Tops Q4 EPS by 10c

Rigel Pharma (NASDAQ: RIGL) reported Q4 EPS of $0.01, $0.10 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $51.3 million versus the consensus estimate of $36.52 million.

As of December 31, 2022, Rigel had cash, cash equivalents and short-term investments of $58.2 million, compared to $125.0 million as of December 31, 2021.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• JPMorgan cuts 2026 box office forecast on slow third quarter
• JPMorgan Upgrades Largan Precision Co Ltd. (3008:TT) to Overweight